[
    [
        {
            "time": "",
            "orginal_text": "【互通资金动向】北上资金连续三个月增持医药生物 爱尔眼科通化东宝成“新宠”",
            "features": {
                "keywords": [
                    "北上资金",
                    "医药生物",
                    "爱尔眼科",
                    "通化东宝"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【互通资金动向】北上资金连续三个月增持医药生物 爱尔眼科通化东宝成“新宠”",
            "scores": {
                "News_content": "【互通资金动向】北上资金连续三个月增持医药生物 爱尔眼科通化东宝成“新宠”",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "豪取15板！中签者便净赚10万，是否高估了，后市怎么走？",
            "features": {
                "keywords": [
                    "15板",
                    "中签",
                    "净赚",
                    "高估",
                    "后市"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "豪取15板！中签者便净赚10万，是否高估了，后市怎么走？",
            "scores": {
                "News_content": "豪取15板！中签者便净赚10万，是否高估了，后市怎么走？",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "【海通医药】中国生物制药17-18Q1经营情况分析：研发与高增长品种驱动未来",
            "features": {
                "keywords": [
                    "海通医药",
                    "中国生物制药",
                    "研发",
                    "高增长品种"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【海通医药】中国生物制药17-18Q1经营情况分析：研发与高增长品种驱动未来",
            "scores": {
                "News_content": "【海通医药】中国生物制药17-18Q1经营情况分析：研发与高增长品种驱动未来",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "四连阴后反弹在即 沪指将构筑“假头肩底”？",
            "features": {
                "keywords": [
                    "四连阴",
                    "反弹",
                    "沪指",
                    "假头肩底"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "四连阴后反弹在即 沪指将构筑“假头肩底”？",
            "scores": {
                "News_content": "四连阴后反弹在即 沪指将构筑“假头肩底”？",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "发改委支持国有、民营企业混改；基金继续看好医药板块",
            "features": {
                "keywords": [
                    "发改委",
                    "国企混改",
                    "民企混改",
                    "基金",
                    "医药板块"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "发改委支持国有、民营企业混改；基金继续看好医药板块",
            "scores": {
                "News_content": "发改委支持国有、民营企业混改；基金继续看好医药板块",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "恒瑞医药股价破百 继续创新高",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "股价破百",
                    "创新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "恒瑞医药股价破百 继续创新高",
            "scores": {
                "News_content": "恒瑞医药股价破百 继续创新高",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "药品注册审评审批优化 利好创新药公司",
            "features": {
                "keywords": [
                    "药品注册",
                    "审评审批",
                    "创新药公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "药品注册审评审批优化 利好创新药公司",
            "scores": {
                "News_content": "药品注册审评审批优化 利好创新药公司",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "15涨停，药明康德何时到顶？总市值已达1231亿！",
            "features": {
                "keywords": [
                    "15涨停",
                    "药明康德",
                    "总市值",
                    "到顶"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "15涨停，药明康德何时到顶？总市值已达1231亿！",
            "scores": {
                "News_content": "15涨停，药明康德何时到顶？总市值已达1231亿！",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        }
    ]
]